[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617908":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":41,"responsibleParty":56,"collaborators":26,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":26,"eligibilityCriteria":63,"healthyVolunteers":60,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":26,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":26,"overallStatus":43,"whyStopped":26,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"pSS Dual-Tracer Imaging Arm (PSMA + FAPI PET)","EXPERIMENTAL","This arm includes patients diagnosed with primary Sjögren's syndrome. All participants undergo both PSMA PET and FAPI PET imaging. The PSMA PET scan is used to assess the functional integrity of salivary gland acinar cells, while the FAPI PET scan evaluates inflammatory and fibroblast activity within the same glands. The purpose of this arm is to characterize the functional-inflammatory relationship in pSS and to develop the combined PSMA\u002FFAPI Index for disease staging and activity assessment.",[13,14],"Diagnostic Test: ⁶⁸Ga-PSMA PET\u002FCT","Diagnostic Test: ⁶⁸Ga-FAPI PET\u002FCT",{"label":16,"type":17,"description":18,"interventionNames":19},"Prostate Cancer PSMA-Only Comparator Arm","ACTIVE_COMPARATOR","This arm consists of patients with prostate cancer who undergo PSMA PET imaging only, representing a population with preserved or physiologic salivary gland PSMA uptake. These scans serve as a reference group for establishing normal or baseline PSMA expression in salivary glands. This comparator arm allows differentiation between disease-related PSMA reduction in pSS and normal tracer distribution observed in patients without salivary gland pathology.",[13],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIAGNOSTIC_TEST","⁶⁸Ga-PSMA PET\u002FCT","PSMA PET imaging performed for clinical evaluation in prostate cancer patients, used as a comparator for physiologic salivary gland PSMA uptake.",[16,9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"⁶⁸Ga-FAPI PET\u002FCT","FAPI PET imaging to assess inflammatory activity (FAPI) in patients with primary Sjögren's syndrome.",[9],[32,37],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Zhaohui Zhu, MD","CONTACT","13611093752","13611093752@163.com",{"name":38,"role":34,"phone":39,"phoneExt":26,"email":40},"Jiarou Wang, MD","13628477019","ChristinaWang97@163.com",[42],{"facility":5,"status":43,"city":44,"state":26,"zip":26,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Beijing","China","CN",{"type":48,"coordinates":49},"Point",[50,51],116.39723,39.9075,{"lat":51,"lon":50},[54,55],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},{"name":38,"role":34,"phone":39,"phoneExt":26,"email":40},{"type":57,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100617908","exploring-the-novel-value-of-psma-pet-in-sjgrens-syndrome-integrated-analysis-with-established-fapi-pet-imaging-100617908",false,"NCT07324733","Exploring the Novel Value of PSMA PET in Sjögren's Syndrome: Integrated Analysis With Established FAPI PET Imaging","Inclusion Criteria:\n\n* Age 18-80 years;\n* Fulfillment of the 2016 ACR-EULAR Classification Criteria for pSS at enrollment. OR diagnosis of a solid tumor scheduled for FAPI PET imaging\n\nExclusion Criteria:\n\n* Combined with tumors or other connective tissue diseases (for SS group);\n* Patients who are currently using hormones\u002Fbiological agents (for both groups)；\n* Pregnancy or lactation","ALL","18 Years","80 Years",{"count":68,"type":69},60,"ESTIMATED","INTERVENTIONAL",[72],"NA","Primary Sjögren's syndrome (pSS) is a chronic autoimmune exocrinopathy characterized by lymphocytic infiltration, progressive destruction of salivary gland acini, and varying degrees of functional impairment and fibrosis. Conventional imaging provides limited ability to simultaneously evaluate glandular function and inflammatory activity, leading to challenges in disease staging and treatment decision-making. This study explores a conceptual dual-tracer imaging framework using PSMA PET and FAPI PET to delineate complementary biological processes in pSS.",[75,76],"Primary Sjögren Syndrome","PET","2025-12-24",{"date":79,"type":80},"2026-01-07","ACTUAL",{"date":82,"type":80},"2025-09-01",{"date":84,"type":69},"2026-05-30",{"name":5,"class":6},1]